Celgene Corporation

Subsidiary of Bristol-Myers Squibb (BMY)

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Cereblon E3 ubiquitin-ligase · Thalidomide AnalogSmall molecule
Multiple MyelomaFollicular LymphomaMyelodysplastic SyndromesMantle Cell Lymphoma
Approved
HDACSmall molecule
Cutaneous T-Cell Lymphoma
Phase 2
mTOR (inhibitor)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 June 2026ApprovalRomidepsinFDA approves Amneal romidepsin injection solution
US, FDA · Source ↗

Financial reports

No financial reports recorded.